Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Part of paid clinical trials in Durham, North Carolina.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05501054
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — DRUG
    Given by IV (vein)
  • Nivolumab — DRUG
    Given by IV (vein)
  • Ciforadenant — DRUG
    Given by PO

Study Details

To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma

Key Dates

Start date
Feb 9, 2023
Status verified
Jan 2026
Primary completion
Nov 1, 2026
Completion
Nov 1, 2026

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ipilimumab, Nivolumab, and Ciforadenant
    To help control advanced renal cell carcinoma.

Primary Outcome Measure

To establish the objective response rate (ORR) [ Time Frame: through study completion and average of 1 year. ]

Locations (3)

FacilityCityStateZIPSite coordinators
Duke Cancer InstituteDurhamNorth Carolina27710-
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104-
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Durham, NC

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Duke Cancer Institute· Durham, NCAbramson Cancer Center of the University of Pennsylvania· Philadelphia, PAM D Anderson Cancer Center· Houston, TX

Related Studies